期刊
EXPERT REVIEW OF HEMATOLOGY
卷 9, 期 2, 页码 137-150出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474086.2016.1122514
关键词
Anaplastic large-cell lymphoma; ALK translocation; NPM-ALK fusion; DUSP22 rearrangements; T-cell non-Hodgkin lymphoma; brentuximab vedotin; crizotinib
类别
资金
- National Cancer Institute [R01 CA177734]
Systemic anaplastic large-cell lymphomas (sALCLs) comprise a heterogeneous group of relatively rare T-cell non-Hodgkin lymphomas (NHLs) characterized by CD30 expression and other unifying pathologic features. Anaplastic lymphoma kinase (ALK) fusions are present in about 50% of cases. Pathological diagnosis can be challenging, particularly in ALK-negative cases. Though ALK-positive and ALK-negative sALCLs are similar morphologically and immunophenotypically, they are separate entities with different genetics, clinical behavior, and outcomes. Evidence-based data evaluating treatment regimens are limited as randomized controlled trials are lacking and most prospective studies are too small to draw definitive conclusions. However, recent advances in molecular biology are bringing forth much-needed knowledge in this field, and are likely to guide further targeted therapeutic development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据